CA19-9 response to NAT alone is not enough to identify long-term post-resection PDAC survivors. The co-existence of CA19-9 and major pathologic response was predictive of the most optimal survival outcome.

2 days ago

Journal

CA 19-9 (Cancer antigen 19-9)

albumin-bound paclitaxel • irinotecan

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . (clinicaltrials.gov)

P=N/A, N=80, Recruiting, Hunan Cancer Hospital

2 days ago

New trial • Combination therapy • Real-world evidence • Real-world • Metastases

Keytruda (pembrolizumab) • Focus V (anlotinib) • Tyvyt (sintilimab) • capecitabine • albumin-bound paclitaxel • fulvestrant • etoposide IV • Halaven (eribulin mesylate)

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)

P3, N=300, Recruiting, Sun Yat-sen University

2 days ago

New P3 trial • Metastases

cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

AK104-217: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)

P2, N=78, Recruiting, Akeso | Not yet recruiting --> Recruiting | N=60 --> 78 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

2 days ago

Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases

gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Kaitanni (cadonilimab)

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC (clinicaltrials.gov)

P2, N=35, Recruiting, Beijing Chest Hospital, Capital Medical University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Aug 2026

2 days ago

Enrollment open • Trial completion date • Trial primary completion date

carboplatin • albumin-bound paclitaxel • Ariely (adebrelimab)

The Optimal Radioimmunotherapy Combinations for Advanced TNBC (clinicaltrials.gov)

P2, N=60, Not yet recruiting, Sun Yat-sen University

3 days ago

New P2 trial • Metastases

carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel

Radiolabelled anti-PD-L1 peptide PET/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. (PubMed, Ann Nucl Med)

Baseline 68Ga-NOTA-WL12 PET/CT has a potential to predict the pathological response of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable NSCLC, whose efficacy is comparable to that of therapy evaluations employing baseline and follow-up CT and 18F-FDG PET/CT examinations.

5 days ago

Journal

PD-L1 (Programmed death ligand 1)

cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • toripalimab subcutaneous (JS001sc)

Chemoradiotherapy in Unresectable Esophageal Cancer (clinicaltrials.gov)

P1/2, N=105, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Sep 2022 --> Dec 2026 | Trial primary completion date: Sep 2022 --> Dec 2025

5 days ago

Trial completion date • Trial primary completion date

cisplatin • albumin-bound paclitaxel

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLS) (MK-3475-01G/KEYMAKER U01) (clinicaltrials.gov)

P2, N=90, Not yet recruiting, Merck Sharp & Dohme LLC

5 days ago

New P2 trial • Combination therapy • Metastases

Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402)

FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)

P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc. | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2027 --> Sep 2027

5 days ago

Trial completion date • Trial initiation date • Trial primary completion date • Metastases

gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial (clinicaltrials.gov)

P2, N=129, Recruiting, Fudan University | Not yet recruiting --> Recruiting

5 days ago

Enrollment open • Metastases

Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)

P3, N=504, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd

5 days ago

New P3 trial • Metastases

carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • ESG401

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)

P1, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025

6 days ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)

Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma (clinicaltrials.gov)

P2, N=45, Recruiting, Sun Yat-sen University

6 days ago

New P2 trial

cisplatin • albumin-bound paclitaxel

QUILT-3.060t: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov)

P1/2, N=6, Terminated, ImmunityBio, Inc. | N=80 --> 6 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

7 days ago

Enrollment change • Trial termination

Avastin (bevacizumab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • GI-4000 • NK92-CD16-158V

ARTEMIDE-Lung02: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=880, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

7 days ago

Enrollment open • Combination therapy • Metastases

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • rilvegostomig (AZD2936)

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (clinicaltrials.gov)

P2, N=401, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2024 --> Sep 2025

7 days ago

Trial completion date • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression • EGFR mutation • ALK fusion

Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed

OSCC: Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov)

P2, N=28, Not yet recruiting, Shanghai Zhongshan Hospital

7 days ago

New P2 trial • Surgery

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)

PD-L1 expression

Erbitux (cetuximab) • cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors (clinicaltrials.gov)

P2, N=134, Recruiting, Tianjin Medical University Cancer Institute and Hospital

7 days ago

New P2 trial

cisplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)

QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov)

P1/2, N=2, Terminated, ImmunityBio, Inc. | Phase classification: P1b/2 --> P1/2 | N=332 --> 2 | Active, not recruiting --> Terminated; low enrollment

8 days ago

Phase classification • Enrollment change • Trial termination • Metastases

Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-021 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC (clinicaltrials.gov)

P2, N=50, Recruiting, Beijing Tongren Hospital

8 days ago

New P2 trial

cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)

P2, N=35, Completed, HonorHealth Research Institute | Active, not recruiting --> Completed | N=10 --> 35 | Trial completion date: Dec 2023 --> Mar 2024

9 days ago

Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases

MUC16 (Mucin 16, Cell Surface Associated)

Opdivo (nivolumab) • cisplatin • gemcitabine • albumin-bound paclitaxel

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)

P2, N=160, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

9 days ago

Enrollment closed • Trial completion date • Trial primary completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)

PD-L1 expression

Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer (clinicaltrials.gov)

P2, N=57, Recruiting, Zhejiang Provincial People's Hospital

9 days ago

New P2 trial

gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab)

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)

P2, N=29, Active, not recruiting, University of Chicago | Trial completion date: Aug 2024 --> Aug 2026

9 days ago

Trial completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

albumin-bound paclitaxel • Korlym (mifepristone)

12d

SMART: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov)

P=N/A, N=27, Not yet recruiting, University of Saskatchewan | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

12 days ago

Trial completion date • Trial primary completion date • Metastases

gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium

13d

Clonal hematopoiesis of indeterminate potential (CHIP) and its association with treatment outcomes and adverse events in patients with solid tumours. (PubMed, Cancer Res Commun)

We reviewed cfDNA results from a local prospective solid tumour cohort (PREDiCT-l) and two randomized trials: CCTG CO.26 (durvalumab + tremelimumab [D+T] or best supportive care in metastatic colorectal cancer) and CCTG PA.7 (gemcitabine and nab-paclitaxel +/- D+T in metastatic pancreatic adenocarcinoma). CHIP is common in patients with solid tumours. Although not appearing to impact rates of adverse events, CHIP may impact outcomes from immunotherapy or chemotherapy.

13 days ago

Journal • Adverse events • PD(L)-1 Biomarker • IO biomarker

DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)

ASXL1 mutation • TET2 mutation

Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab)

13d

Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (PubMed, Pharmacol Res)

Hormonal or endocrine therapy includes selective estrogen receptor modulators (SERMs) such as raloxifene, tamoxifen and toremifene, selective estrogen-receptor degraders (SERDs) including elacestrant and fulvestrant, and aromatase inhibitors such as anastrozole, letrozole, and exemestane...These agents include taxanes (docetaxel, nab-paclitaxel, and paclitaxel), anthracyclines (doxorubicin, epirubicin), anti-metabolites (capecitabine, gemcitabine, fluorouracil, methotrexate), alkylating agents (carboplatin, cisplatin, and cyclophosphamide), and drugs that target microtubules (eribulin, ixabepilone, ado-trastuzumab emtansine). Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.

13 days ago

Review • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative • HER-2 positive + HR negative

cisplatin • carboplatin • gemcitabine • docetaxel • 5-fluorouracil • tamoxifen • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • capecitabine • albumin-bound paclitaxel • cyclophosphamide • fulvestrant • Halaven (eribulin mesylate) • methotrexate • letrozole • epirubicin • anastrozole • exemestane • Orserdu (elacestrant) • Ixempra (ixabepilone) • raloxifene hydrochloride

14d

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer (clinicaltrials.gov)

P2, N=46, Recruiting, Wake Forest University Health Sciences | Suspended --> Recruiting

14 days ago

Enrollment open • Metastases

gemcitabine • albumin-bound paclitaxel

14d

AK104-IIT-C-N1-0122: AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC (clinicaltrials.gov)

P2, N=30, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting

14 days ago

Enrollment open • Metastases

gemcitabine • Rituxan (rituximab) • albumin-bound paclitaxel • Kaitanni (cadonilimab)

14d

FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)

P1/2, N=30, Recruiting, Lisata Therapeutics, Inc. | Not yet recruiting --> Recruiting

14 days ago

Enrollment open • Metastases

gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)

14d

CRTOG2401: Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC (clinicaltrials.gov)

P2, N=86, Recruiting, Anhui Provincial Cancer Hospital

14 days ago

New P2 trial

cisplatin • carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel

14d

TTX-030-003: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)

P2, N=194, Active, not recruiting, Trishula Therapeutics, Inc. | Recruiting --> Active, not recruiting

14 days ago

Enrollment closed • Metastases

gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • TTX-030

15d

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers (clinicaltrials.gov)

P1, N=40, Recruiting, iOnctura | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

15 days ago

Trial completion date • Trial primary completion date

gemcitabine • albumin-bound paclitaxel • cambritaxestat (IOA-289)

15d

Phase II randomized controlled trial to evaluate the supportive effect of Koujin (TJ-3020) powder in gemcitabine and nab-paclitaxel-treated unresectable or recurrent pancreatic cancer. (PubMed, Pancreas)

In this phase II randomized trial, oral administration of red ginseng powder at 2.0 g per day did not reduce pancreatic cancer patients' fatigue or malaise induced by GnP combination chemotherapy.

15 days ago

P2 data • Journal

CA 19-9 (Cancer antigen 19-9)

gemcitabine • albumin-bound paclitaxel

15d

Management of Symptomatic Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)

P=N/A, N=110, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Unknown status --> Active, not recruiting | Trial completion date: Oct 2020 --> Jan 2025

15 days ago

Enrollment closed • Trial completion date • Metastases

5-fluorouracil • albumin-bound paclitaxel • irinotecan

16d

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)

P2, N=30, Not yet recruiting, Shandong Cancer Hospital and Institute

16 days ago

New P2 trial • Metastases

Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • Cosela (trilaciclib)

16d

A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China (PubMed, Zhonghua Zhong Liu Za Zhi)

Further analysis revealed that mutations in CDKN2B, PTEN, FGF6, and RBBP8 genes were significantly associated with an increased risk of death (P＜0.05). Albumin-bound paclitaxel as first-line treatment demonstrated feasible anti-tumor efficacy and manageable safety for patients with advanced pancreatic cancer in China.

16 days ago

Journal • Real-world evidence • Real-world • Metastases

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • RBBP8 (RB Binding Protein 8, Endonuclease)

TP53 mutation • KRAS mutation • PTEN mutation

albumin-bound paclitaxel

16d

Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer. (PubMed, Br J Clin Pharmacol)

The ABCB1 C3435T (rs1045642) TT genotype was significantly associated with early, extremely severe neutropenia in patients receiving paclitaxel/nab-paclitaxel. Evaluating this genotype status may help predict those at increased risk for early, extremely severe neutropenia.

16 days ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1)

ABCB1 C3435T • ABCB1 G2677T

albumin-bound paclitaxel • Cyramza (ramucirumab)

16d

SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) (clinicaltrials.gov)

P2, N=51, Recruiting, Hubei Cancer Hospital | Not yet recruiting --> Recruiting

16 days ago

Enrollment open

carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • Kaitanni (cadonilimab)

17d

SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer (clinicaltrials.gov)

P2, N=50, Recruiting, Hubei Cancer Hospital | Not yet recruiting --> Recruiting

17 days ago

Enrollment open

doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • Yidafan (ivonescimab)